BLUE BELL, Pa., Sept. 6, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, has expanded its
scientific advisory board with the appointment of two prominent
leaders in the fields of vaccines and cancer immunotherapeutics.
Joining Inovio’s advisory board are Dr. Thomas S. Edgington,
Emeritus Professor of the Scripps Research Institute and founder of
several biotechnology companies; and Dr. Philip D. Greenberg,
Professor of Medicine (Oncology) and Immunology, Department of
Medicine, University of Washington.
Dr. Thomas S. Edgington is an emeritus professor of the
Scripps Research Institute. Dr. Edgington served as the president
and a board member of the Federation of American Societies for
Experimental Biology (FASEB). He was founder and Chairman of the
Board of Directors of Corvas International, Inc., which was
acquired by Dendreon. Dr. Edgington also founded Molecular Biology
Consultants Inc., BioSequences Ltd. and NuVas LLC. He served as a
director of Apollon, one of the earliest DNA vaccine companies,
which was acquired by Wyeth. He served as a member of the
scientific advisory board of Halozyme Therapeutics, Inc. Dr.
Edgington is a member of the U.S. National Academy of Sciences and
the Institute of Medicine. He has over 500 publications in the
biomedical sciences and filed over 25 patents.
Dr. Philip D. Greenberg is Professor of Medicine
(Oncology) and Immunology, Department of Medicine, University of
Washington and heads the Program in Immunology at the Fred
Hutchinson Cancer Research Center. Dr. Greenberg has had a
long-standing research career elucidating the principles that
underlie T-cell recognition of viruses and cancer cells,
determining why such responses often fail to eliminate the viral
pathogen or cancer, and developi